IMM
NEUTRALImmuPharma Provides Corporate Update on P140 Partnership Discussions
The biopharmaceutical company provides an update on its discussions with potential partners for the development and commercialization of its P140 autoimmune platform.
ImmuPharma
6.20GBX
1.64%
Market Cap
31.17M
Volume
1.64M
42% of avg
P/E Ratio
-1.83
EPS (TTM)
-3.39
Beta
3.03
Day Range
5.90p - 6.44p
52 Week Range
1.03p6.20p19.40p
6.20p
Upcoming Events
2030
Relevant therapy markets forecast to reach global sales of c.$360 billion
High Impact Event
IMM
NEUTRALImmuPharma Announces Holding(s) in Company
The healthcare company has received a notification of a change in major shareholding.
IMM
NEUTRALImmuPharma Attending Bio-Europe Conference
The biopharmaceutical company is attending an industry conference in Vienna.
IMM
NEUTRALImmuPharma Launches New Website, Highlights P140 Autoimmune Platform
The biopharmaceutical company has launched a new corporate website, showcasing its proprietary P140 autoimmune platform and plans for potential partnerships.
IMM
NEUTRALImmuPharma Appoints New Independent Non-Executive Director
The healthcare company has appointed an experienced investment professional to its board as an independent non-executive director.
IMM
NEUTRALImmuPharma Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
IMM
BADImmuPharma Raises £25,000 Through Warrant Exercise
The biopharmaceutical company has raised £25,000 through the exercise of warrants, issuing new shares at a 66.4% discount to the previous closing price.
IMM
NEUTRALImmuPharma Announces Exercise of Warrants
The biopharmaceutical company has received notice of the exercise of 2.5 million warrants, representing 0.5% of the enlarged share capital.
IMM
NEUTRALImmuPharma Appoints New Chief Scientific Officer and Head of R&D
The biopharmaceutical company has made key appointments to its R&D leadership team.
IMM
NEUTRALImmuPharma Files New Patent Application for P140
The biopharmaceutical company has filed a new patent application for its lead asset P140, which could provide 20 years of commercial exclusivity and enable a precision approach to treating autoimmune diseases.